



## BioCryst to Present at Upcoming Investor Conferences

February 19, 2025

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

- TD Cowen 45<sup>th</sup> Annual Health Care Conference in Boston on Wednesday, March 5, 2025, at 9:10 a.m. ET.
- Barclays 27<sup>th</sup> Annual Global Healthcare Conference in Miami on Tuesday, March 11, 2025, at 10:00 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst's website at <http://www.biocryst.com>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO<sup>®</sup> (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit [www.biocryst.com](http://www.biocryst.com) or follow us on [LinkedIn](#).

BCRXW

### Contact:

John Bluth  
+1 919 859 7910  
[jbluth@biocryst.com](mailto:jbluth@biocryst.com)